Compare CRSP & HWC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | CRSP | HWC |
|---|---|---|
| Founded | 2013 | 1883 |
| Country | Switzerland | United States |
| Employees | N/A | 3627 |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Major Banks |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.9B | 5.2B |
| IPO Year | 2016 | N/A |
| Metric | CRSP | HWC |
|---|---|---|
| Price | $53.57 | $66.34 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 6 |
| Target Price | $70.29 | ★ $77.67 |
| AVG Volume (30 Days) | ★ 1.6M | 735.3K |
| Earning Date | 05-11-2026 | 04-21-2026 |
| Dividend Yield | N/A | ★ 3.00% |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $289,590,000.00 | N/A |
| Revenue This Year | $807.72 | $11.59 |
| Revenue Next Year | $172.52 | $4.42 |
| P/E Ratio | ★ N/A | $12.48 |
| Revenue Growth | ★ 9169.85 | N/A |
| 52 Week Low | $33.03 | $52.89 |
| 52 Week High | $78.48 | $75.43 |
| Indicator | CRSP | HWC |
|---|---|---|
| Relative Strength Index (RSI) | 52.63 | 48.87 |
| Support Level | $50.91 | $66.40 |
| Resistance Level | $60.45 | $68.09 |
| Average True Range (ATR) | 2.72 | 1.65 |
| MACD | -0.31 | -0.19 |
| Stochastic Oscillator | 42.74 | 11.48 |
Crispr Therapeutics is a gene editing company focused on the development of Crispr/Cas9-based therapeutics. Crispr/Cas9 stands for clustered regularly interspaced short palindromic repeats (Crispr)/Crispr-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. Crispr's first approved drug is Casgevy, which was developed in collaboration with Vertex Pharmaceuticals and targets sickle-cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is advancing a variety of gene editing programs in immuno-oncology, cardiovascular, and a stem cell-derived therapy to treat Type 1 diabetes.
Hancock Whitney Corp operates bank offices and financial centers. The company offers a range of traditional and online banking services to commercial, small business, and retail customers, providing a variety of transaction and savings deposit products, treasury management services, secured and unsecured loan products (including revolving credit facilities), letters of credit, and similar financial guarantees. The Bank provides trust and investment management services to retirement plans, corporations, and individuals and provides its customers access to investment advisory and brokerage products.